These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 15367403)
1. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Punt CJ Ann Oncol; 2004 Oct; 15(10):1453-9. PubMed ID: 15367403 [TBL] [Abstract][Full Text] [Related]
2. [Recent results of irinotecan therapy in colorectal cancer]. Láng I; Hitre E Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC? Loupakis F; Falcone A Nat Rev Clin Oncol; 2010 Apr; 7(4):190-1. PubMed ID: 20354542 [TBL] [Abstract][Full Text] [Related]
4. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. Grivicich I; Mans DR; Peters GJ; Schwartsmann G Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832 [TBL] [Abstract][Full Text] [Related]
5. Induction therapy in patients with metastatic colorectal cancer. Venook AP Semin Oncol; 2003 Aug; 30(4 Suppl 12):25-9. PubMed ID: 14508724 [No Abstract] [Full Text] [Related]
6. Oxaliplatin: a new agent for colorectal cancer. Pelley RJ Curr Oncol Rep; 2001 Mar; 3(2):147-55. PubMed ID: 11177747 [TBL] [Abstract][Full Text] [Related]
7. Second line therapies move to the forefront in colorectal cancer. Miller M J Natl Cancer Inst; 1999 Jun; 91(12):998-1000. PubMed ID: 10379961 [No Abstract] [Full Text] [Related]
9. Systemic treatment of advanced colorectal carcinoma. van Laarhoven HW; Punt CJ Eur J Gastroenterol Hepatol; 2004 Mar; 16(3):283-9. PubMed ID: 15195891 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454 [TBL] [Abstract][Full Text] [Related]
11. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Lloyd Jones M; Hummel S; Bansback N; Orr B; Seymour M Health Technol Assess; 2001; 5(25):1-128. PubMed ID: 11990245 [No Abstract] [Full Text] [Related]
12. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Yamaguchi T Drug Des Devel Ther; 2015; 9():3099-108. PubMed ID: 26124634 [TBL] [Abstract][Full Text] [Related]
13. Current approaches to first-line treatment of advanced colorectal cancer. Goldberg RM Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S9-15. PubMed ID: 15212700 [TBL] [Abstract][Full Text] [Related]
16. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Volk J; Reinke F; van Kuilenburg AB; van Gennip AH; Schlichting C; Ganser A; Schöffski P Ann Oncol; 2001 Apr; 12(4):569-71. PubMed ID: 11398894 [TBL] [Abstract][Full Text] [Related]
17. The combination of capecitabine and oxaliplatin in metastatic colorectal cancer. Clin Colorectal Cancer; 2003 Feb; 2(4):205-9. PubMed ID: 12620138 [No Abstract] [Full Text] [Related]